Harvard Apparatus Regenerative Technology, Inc. is asking stockholders to vote at its 2026 Annual Meeting on three key items: electing three Class I directors, ratifying CBIZ CPAs P.C. as auditor for 2026, and approving a non-binding advisory vote on named executive officer pay.
The meeting will be held in person on June 18, 2026 at 9:30 a.m. Eastern Time at the company’s Holliston, Massachusetts headquarters. Stockholders of record as of April 21, 2026, when 17,580,744 common shares were outstanding, are entitled to vote one share per share held. The board states that all directors except the CEO are independent and recommends voting “FOR” all three proposals.
The proxy details board and committee structure, director biographies, executive employment terms, and 2025 compensation. CEO Junli (Jerry) He received total 2025 compensation of $439,969, while other named executives received between about $188,000 and $228,000. The filing also describes equity incentive plans, ownership of major shareholders and insiders, related-party bridge loans from the CEO, and the transition of audit work from Marcum LLP to CBIZ CPAs P.C.
Harvard Apparatus Regenerative Technology, Inc. entered into a related-party bridge loan with its Chairman and CEO, Junli He, for $300,000, documented in a Bridge Note bearing a fixed 8% annual interest rate.
The principal and accrued interest are due on the earlier of the company’s next capital raise with at least $5,000,000 in gross proceeds or April 13, 2027. The Bridge Note includes optional conversion at the lender’s discretion, covenants, and customary events of default such as failure to pay amounts due or comply with its terms.
Harvard Apparatus Regenerative Technology, Inc. (HRGN) is a clinical-stage regenerative medicine company developing cell-based implants to restore damaged organs, initially focusing on the esophagus. Its Cellspan Esophageal Implant uses a patient’s own mesenchymal stem cells seeded on a removable polyurethane scaffold to regenerate functional tissue without permanent implants or donor organs.
The FDA has approved an investigational phase 1 trial in up to ten U.S. patients who need resection of up to six centimeters of esophagus; three sites are activated, but the company has yet to enroll its first eligible patient due to strict criteria and logistical hurdles. HRGN leverages encouraging data from over 50 pig procedures and a first-in-human compassionate-use case at Mayo Clinic, and holds U.S. and EU orphan drug designations that could provide multi-year market exclusivity if a product is approved.
The pipeline extends to pediatric esophageal atresia, colon reconstruction and uterine adhesion prevention, supported by collaborations with institutions including Mayo Clinic, Connecticut Children’s and Capital Medical University in China. The company also runs a Hong Kong subsidiary for consumer health products. Research and development expenses were about $2.7 million in 2025 and $2.3 million in 2024. As of March 9, 2026, HRGN had 17,580,744 common shares outstanding, and non-affiliate equity market value was approximately $15.6 million as of June 30, 2025 at a $1.70 share price.
Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors for a private placement of its common stock. The investors agreed to buy an aggregate of 411,765 shares of common stock at a purchase price of $1.70 per share, for an aggregate purchase price of approximately $0.7 million.
The shares were sold in a private transaction relying on exemptions from Securities Act registration, including Section 4(a)(2) for transactions not involving a public offering and Rule 506 for sales to an accredited investor, as well as similar state law exemptions. The Purchase Agreements contain customary representations, warranties, and covenants, and a form of the agreement is filed as an exhibit to the report.
Harvard Apparatus Regenerative Technology, Inc. reported an insider share purchase by its CEO. The company’s Chief Executive Officer and Director, based on this filing, bought 3,000 shares of common stock on 11/25/2025 in an open-market transaction coded “P” for a purchase. The weighted average purchase price reported was $1.70 per share, reflecting multiple trades between November 25 and November 26. Following this transaction, the reporting person beneficially owned 280,575 shares of Harvard Apparatus Regenerative Technology common stock held directly.
Harvard Apparatus Regenerative Technology (HRGN) filed its Q3 2025 10‑Q, reporting higher consumer health sales on a small base and continued operating losses, alongside a going concern warning. Q3 product revenue was $123,000 (vs. $59,000 a year ago), and the net loss was $1.7 million (vs. $1.9 million). For the first nine months, revenue reached $485,000 (vs. $172,000), while the net loss narrowed to $5.2 million (vs. $6.4 million), helped by lower selling, marketing, and G&A expenses.
Cash and equivalents were $1.3 million at September 30, 2025. Management states these funds are expected to support operations into the fourth quarter of 2025, raising substantial doubt about the company’s ability to continue as a going concern. The company completed a private placement on July 11, 2025, issuing 1,250,000 shares for gross proceeds of $2.0 million.
Deferred revenue was $128,000, and warrants outstanding totaled 898,622 with a weighted‑average exercise price of $5.33. 17,168,979 common shares were outstanding as of November 3, 2025.
He Junli, who serves as Chief Executive Officer and a director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), purchased 11,225 shares of HRGN common stock in transactions executed between September 2, 2025 and September 22, 2025 at a weighted average price of $1.85 per share. Following these purchases the reporting person beneficially owned 277,275 shares. The Form 4 was signed by a power of attorney on September 24, 2025. The filing discloses no derivative transactions and notes the weighted average price reflects multiple trades; the reporting person will supply transaction-level price details on request.